Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2025-06-04 00:00:00 ET · period of report 2025-06-02 · accession 0001415889-25-015574 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-04 | 2025-06-02 | TSHA | Stalfort John A III | Dir | A - Grant | $0.00 | +56.6K | 1.16M | +5% | $0 |
| D | 2025-06-04 | 2025-06-02 | TSHA | Stalfort John A III | Dir | A - Grant | $0.00 | +113.2K | 113.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-02 | A | A | 56,623 | $0.00 | 1,155,224 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-06-02 | A | A | 113,246 | $0.00 | 113,246 | D | $2.79 · — to 2035-06-02 | 113,246 Common Stock | (F3) The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |